Xuanting Wang

发表

MLC Seq: De novo sequencing of full-length tRNA isoforms by mass ladder complementation

J. Russo, X. Bao, Qi Chen, 2021, bioRxiv.

A General LC-MS-Based Method for Direct and De Novo Sequencing of RNA Mixtures Containing both Canonical and Modified Nucleotides.

Tony Z. Jia, B. Yoo, S. Shi, 2021, Methods in molecular biology.

Identifying Structural Features of Nucleotide Analogues to Overcome SARS-CoV-2 Exonuclease Activity

J. Ju, J. Russo, Shiv Kumar, 2022, Viruses.

Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors than Isoflavone and Flavones

Carolina Q. Sacramento, J. Ju, J. Russo, 2022, Viruses.

Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture

Carolina Q. Sacramento, T. Tuschl, D. Patel, 2022, Communications biology.

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19

Carolina Q. Sacramento, T. Tuschl, D. Patel, 2021, The Journal of antimicrobial chemotherapy.

Direct sequencing of tRNA by 2D-HELS-AA MS Seq reveals its different isoforms and dynamic base modifications.

Tony Z. Jia, J. Russo, B. Yoo, 2020, ACS chemical biology.

2D-HELS-AA MS Seq: Direct sequencing of tRNA reveals its different isoforms and multiple dynamic base modifications

Tony Z. Jia, J. Russo, B. Yoo, 2019 .

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

T. Tuschl, D. Patel, S. Jockusch, 2020, bioRxiv.

Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics

Carolina Q. Sacramento, T. Tuschl, D. Patel, 2021, bioRxiv.